NMN and Blood Pressure

NMN and Blood Pressure is one of the most searched questions among people exploring nicotinamide mononucleotide supplementation. With cardiovascular disease remaining the leading cause of death globally, any supplement that might influence vascular health deserves rigorous scrutiny. The question is whether the existing human evidence supports a blood-pressure benefit — or if we are still in the early, hypothesis-building phase.

The Evidence Base

Human trials on NMN and blood pressure specifically are limited. No published randomized controlled trial to date has used systolic or diastolic blood pressure as a primary endpoint. What we have are secondary or exploratory findings from studies designed for other outcomes — insulin sensitivity, muscle function, aerobic capacity, and NAD+ metabolism.

Yoshino et al. (2021) conducted a randomized, placebo-controlled, crossover trial in prediabetic women. Participants received 250 mg NMN daily for 10 weeks. The primary outcome was muscle insulin sensitivity, which improved significantly. Blood pressure was not a predefined endpoint, and the paper does not report formal blood-pressure analysis. This means we cannot draw conclusions about NMN and blood pressure from this study, but it does establish that NMN is bioactive in humans at moderate doses.

Igarashi et al. (2022) studied healthy older men given 250 mg NMN daily for 12 weeks. The trial focused on muscle function and NAD+ kinetics. Again, blood pressure was not a primary or secondary outcome reported in the main results. Irie et al. (2020) administered NMN to healthy Japanese men at doses ranging from 100 to 500 mg, observing safety and metabolite levels. No clinically significant changes in blood pressure were noted, though the sample was small and the study was not powered for cardiovascular endpoints.

Liao et al. (2021) tested NMN in amateur runners at 300–600 mg daily for 6 weeks, measuring aerobic capacity. Niu et al. (2023) examined pre-aging adults with 300 mg NMN for 8 weeks, focusing on metabolism and telomere length. Neither trial reported blood-pressure data as an outcome. In short, the direct human evidence linking NMN to blood-pressure reduction is currently absent. We are left with mechanistic inference and preclinical data.

Study	Population	NMN Dose	Duration	Blood Pressure Reported?	Primary Outcome
Yoshino et al. (2021)	Prediabetic women	250 mg/day	10 weeks	No	Muscle insulin sensitivity
Igarashi et al. (2022)	Healthy older men	250 mg/day	12 weeks	No	Muscle function, NAD+ levels
Irie et al. (2020)	Healthy Japanese men	100–500 mg/day	Single and repeated doses	No formal analysis	Safety, metabolite levels
Liao et al. (2021)	Amateur runners	300–600 mg/day	6 weeks	No	Aerobic capacity
Niu et al. (2023)	Pre-aging adults	300 mg/day	8 weeks	No	Metabolism, telomere length

The Mechanism

Despite the lack of direct clinical data, the mechanistic rationale for why NMN might influence blood pressure is biologically plausible. NMN is a direct precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy metabolism, sirtuin activation, and oxidative stress responses. Vascular function depends heavily on NAD+ availability, particularly in the endothelium.

Gomes et al. (2013) demonstrated that declining NAD+ during aging disrupts nuclear-mitochondrial communication, creating a pseudohypoxic state. In this state, cells behave as if oxygen is low even when it is not, triggering hypoxia-inducible factor (HIF-1α) and reducing mitochondrial efficiency. Endothelial cells are especially vulnerable to this pseudohypoxic shift because they rely on continuous mitochondrial ATP production to maintain vascular tone and nitric oxide bioavailability.

Nitric oxide (NO) is the primary vasodilator produced by endothelial cells. Its synthesis by endothelial nitric oxide synthase (eNOS) requires NADPH, which is generated through NAD+-dependent pathways. If NAD+ depletion impairs eNOS coupling or increases reactive oxygen species, NO bioavailability falls and vascular resistance rises. Restoring NAD+ via NMN could, in theory, reverse this endothelial dysfunction and lower blood pressure. This is the core hypothesis, but it remains largely untested in humans.

Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase, also regulates vascular health. SIRT1 deacetylates and activates eNOS, promoting vasodilation. In animal models, NMN administration has been shown to activate SIRT1 in endothelial cells and improve arterial stiffness. Whether this translates to measurable blood-pressure changes in people is unknown. The mechanistic story is compelling; the clinical confirmation is not.

What the Evidence Does Not Show

It is important to be explicit about the gaps. No human study has demonstrated that NMN lowers systolic or diastolic blood pressure in a statistically significant, dose-dependent manner. No meta-analysis has pooled data for this endpoint. No trial has specifically enrolled hypertensive participants to test NMN as an antihypertensive intervention.

The absence of evidence is not evidence of absence. NMN may well have blood-pressure benefits that current trials were too small, too short, or too narrowly designed to detect. But as of now, claiming that NMN reduces blood pressure in humans would be unsupported. Anyone considering NMN for cardiovascular health should understand this distinction clearly.

Another limitation is dose standardization. The human trials used 100–600 mg daily, but optimal dosing for vascular endpoints is undefined. Higher doses might be necessary for endothelial effects, or lower doses might suffice if tissue-specific uptake differs. We do not know. Pharmacokinetic data from Irie et al. (2020) show that oral NMN raises blood NAD+ metabolites, but tissue distribution — especially in vascular endothelium — has not been quantified in humans.

Who Benefits Most

Given the uncertainty, who might reasonably consider NMN with blood pressure in mind? The evidence is strongest for populations with NAD+ depletion and metabolic dysfunction, even if blood pressure was not the measured outcome.

Prediabetic women in the Yoshino et al. (2021) trial showed improved insulin sensitivity, a marker closely linked to vascular health. Insulin resistance and hypertension often coexist, and improving one frequently benefits the other. Older adults, the population studied by Igarashi et al. (2022), are also plausible candidates because NAD+ declines with age and arterial stiffness increases. However, these are inferences, not proven indications.

Athletes and physically active individuals, as studied by Liao et al. (2021), may experience peripheral vascular adaptations from training that overlap with any NMN effect. Whether NMN adds incremental benefit to exercise-induced vascular improvements is unclear. For individuals with established hypertension on medication, NMN should not replace standard therapy. Any adjunct use should be discussed with a clinician, ideally within a framework that monitors blood pressure objectively.

Those interested in the vascular angle may also want to explore related topics. Our article on NMN and Cardiovascular Health examines the broader heart and vessel context, while NMN and Endothelial Function focuses specifically on the lining of the arteries. For readers comparing supplements, Magnesium and Blood Pressure covers a mineral with stronger direct clinical evidence for blood-pressure reduction.

Practical Takeaways

• Do not rely on NMN as a primary blood-pressure treatment. The human evidence does not support antihypertensive efficacy at this time.
• Consider NMN for metabolic and vascular aging support. The mechanistic rationale is sound, but clinical translation remains unproven.
• Doses in human trials range from 250–600 mg daily. Bio:sudo NMN 1000mg provides a higher dose than most studied protocols, but optimal dosing for vascular outcomes is unknown.
• Monitor your own data. If you use NMN and have hypertension, track home blood pressure before and during supplementation. Objective self-monitoring is more reliable than subjective impressions.
• Pair with proven lifestyle interventions. Exercise, sodium reduction, and weight management have robust blood-pressure evidence. NMN, if beneficial, is likely additive rather than substitutive.
• Watch for future trials. The field is evolving rapidly. Blood-pressure-specific RCTs are needed and may appear within the next few years.

Bottom Line

The mechanistic case for NMN influencing blood pressure through NAD+ restoration, SIRT1 activation, and endothelial nitric oxide biology is scientifically coherent. However, no human trial to date has tested or confirmed this hypothesis directly. NMN and Blood Pressure remains an open question — one that should be approached with curiosity, but not with the expectation of a proven clinical benefit. For those already using NMN for energy, metabolism, or healthy aging, vascular effects may be a secondary consideration; for those seeking a blood-pressure-specific supplement, the evidence is not yet there.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---